{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:35:57Z","timestamp":1791380157800,"version":"4.3.3"},"reference-count":33,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017104","name":"Yokohama City University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015993","name":"Kowa Company, Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,10,25]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Non-alcoholic fatty liver disease, now known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a phenotype of the metabolic syndrome in the liver and is clearly associated with metabolic abnormalities such as hyperglycaemia and dyslipidaemia. Although the prevalence of MASLD is increasing worldwide, there is currently no consensus on the efficacy and safety of the drugs used to treat MASLD\/metabolic dysfunction-associated steatohepatitis (MASH). Pemafibrate, a selective peroxisome proliferator-activated receptor alpha modulator, was designed to have higher peroxisome proliferator-activated receptor alfa (PPAR\u03b1) agonist activity and selectivity than existing PPAR\u03b1 agonists, and in development trials, without increasing creatinine levels, lipid parameters and alanine aminotransferase (ALT) were significantly improved. Thus, pemafibrate may effectively ameliorate the pathogenesis and metabolic abnormalities in MASLD\/MASH. In this trial, we evaluated the efficacy and safety of pemafibrate in patients with MASLD\/MASH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This trial was designed as an open-label, three-arm, randomised controlled study. After obtaining informed consent, patients aged 20\u201380 years who met the selection criteria were enrolled. Patients were randomised to receive pemafibrate 0.4 mg\/day, 0.2 mg\/day or fenofibrate (n=120 per group). The duration of treatment was 48 weeks. The primary endpoint was a change in ALT levels after 24 weeks of administration. Secondary endpoints included changes from baseline in liver fibrosis markers (fibrosis-4 index, type IV collagen 7s, enhanced liver fibrosis and Mac-2 binding protein glycosylation isomer) at 48 weeks as well as changes in liver fat mass and liver stiffness measured by MRI and ultrasound (US) at centres equipped with MRI and US capabilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval was obtained from the Yokohama City University Certified Institutional Review Board before participant enrolment (CRB20-014). The results of this study will be submitted for publication in international peer-reviewed journals and the key findings will be presented at international scientific conferences. Participants wishing to understand the results of this study will be contacted directly on data publication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>This trial was registered in the Japan Registry of Clinical Trials (number: jRCTs031200280).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Protocol version<\/jats:title>\n                    <jats:p>V.1.9, 23 November 2023<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-088862","type":"journal-article","created":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T14:36:09Z","timestamp":1732458969000},"page":"e088862","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7650-0699","authenticated-orcid":false,"given":"Michihiro","family":"Iwaki","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine Graduate School of Medicine, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine Graduate School of Medicine, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Nogami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine Graduate School of Medicine, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organisation Yokohama Medical Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Imajo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shin Yurigaoka General Hospital, Kawasaki, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Yokohama Sakae Kyosai Hospital, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Nakada","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Shonan Hospital, Yokosuka, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, NamikiKoiso-Medical Clinic, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Kurihashi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kanagawa Dental University Yokohama Clinic, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Oza","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatology, Saga Prefecture Medical Center Koseikan, Saga, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Kohira","sequence":"additional","affiliation":[{"name":"Loco Medical General Institute, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Karatsu Red Cross Hospital, Karatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Masuda Red Cross Hospital, Masuda, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Iwane","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fujioka Hospital, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujito","family":"Kageyama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hamamatsu Medical Center, Hamamatsu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Sasada","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Iwata City Hospital, Iwata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shimada Municipal Hospital, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimitsu","family":"Tadauchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Seirei Mikatahara Byoin, Hamamatsu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gou","family":"Murohisa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Seirei Hamamatsu Byoin, Hamamatsu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Nagasawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Seirei Hamamatsu Byoin, Hamamatsu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Izumo City General Medical Center, Izumo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kitasenri Maeda Clinic, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Furuta","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Hamada Medical Center, Hamada, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Shigefuku","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine Faculty of Medicine, Tsu, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Seko","sequence":"additional","affiliation":[{"name":"Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tobita","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Shimane University Hospital, Shimane, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Kawata","sequence":"additional","affiliation":[{"name":"Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Kawanaka","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine 2, Kawasaki Medical Center, Kawasaki Medical School, Kurashiki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Sugihara","sequence":"additional","affiliation":[{"name":"Division of Medicine and Clinical Science, Department of Multidisciplinary Internal Medicine, Tottori University Faculty of Medicine Graduate School of Medicine, Yonago, Tottori, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoh","family":"Iwasa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine Faculty of Medicine, Tsu, Mie, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Itoh","sequence":"additional","affiliation":[{"name":"Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Education and Research Center for Community Medicine, Faculty of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Endocrinology, Liver Center, Saga University Hospital, Saga, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6263-1436","authenticated-orcid":false,"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine Graduate School of Medicine, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine Graduate School of Medicine, Yokohama, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,11,24]]},"reference":[{"key":"2025120518560398000_14.11.e088862.1","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","article-title":"Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease","volume":"79","author":"Kanwal","year":"2024","journal-title":"Hepatology"},{"key":"2025120518560398000_14.11.e088862.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-012-0533-z"},{"key":"2025120518560398000_14.11.e088862.3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.05.041"},{"key":"2025120518560398000_14.11.e088862.4","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstr\u00f6m","year":"2024","journal-title":"J Hepatol"},{"key":"2025120518560398000_14.11.e088862.5","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jhep.2023.07.017","article-title":"Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD","volume":"80","author":"Ratziu","year":"2024","journal-title":"J Hepatol"},{"key":"2025120518560398000_14.11.e088862.6","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.jhep.2023.08.021","article-title":"Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD","volume":"80","author":"Chen","year":"2024","journal-title":"J Hepatol"},{"key":"2025120518560398000_14.11.e088862.7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23276"},{"key":"2025120518560398000_14.11.e088862.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05042.x"},{"key":"2025120518560398000_14.11.e088862.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2007.10.002"},{"key":"2025120518560398000_14.11.e088862.10","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1097\/MEG.0000000000000981","article-title":"Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease","volume":"29","author":"Yaghoubi","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025120518560398000_14.11.e088862.11","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9633-1"},{"key":"2025120518560398000_14.11.e088862.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2007.05.066"},{"key":"2025120518560398000_14.11.e088862.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.10.006"},{"key":"2025120518560398000_14.11.e088862.14","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13900","article-title":"Drug-drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open-label, randomized, 6-sequence, 3-period crossover studies","volume":"17","author":"Kamimura","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2025120518560398000_14.11.e088862.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1006581"},{"key":"2025120518560398000_14.11.e088862.16","first-page":"387","article-title":"SERUM ENZYME LEVELS IN THE DIAGNOSIS OF HEPATIC DISEASE","volume":"40","author":"ZIMMERMAN","year":"1963","journal-title":"Am J Gastroenterol"},{"key":"2025120518560398000_14.11.e088862.17","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(59)90175-5"},{"key":"2025120518560398000_14.11.e088862.18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22109"},{"key":"2025120518560398000_14.11.e088862.19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.5551\/jat.44412","article-title":"Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial","volume":"25","author":"Arai","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"2025120518560398000_14.11.e088862.20","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/dom.13686","article-title":"Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52\u2010week data from the PROVIDE study","volume":"21","author":"Araki","year":"2019","journal-title":"Diabetes Obesity Metabolism"},{"key":"2025120518560398000_14.11.e088862.21","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1589"},{"key":"2025120518560398000_14.11.e088862.22","doi-asserted-by":"publisher","DOI":"10.1177\/0004563215608875"},{"key":"2025120518560398000_14.11.e088862.23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jphs.2017.02.003","article-title":"Effects of K-877, a novel selective PPAR\u03b1 modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice","volume":"133","author":"Takei","year":"2017","journal-title":"J Pharmacol Sci"},{"key":"2025120518560398000_14.11.e088862.24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-06542-8","article-title":"Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy","volume":"12","author":"Kanno","year":"2022","journal-title":"Sci Rep"},{"key":"2025120518560398000_14.11.e088862.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.03.003"},{"key":"2025120518560398000_14.11.e088862.26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/jdi.12621","article-title":"Selective peroxisome proliferator-activated receptor-\u03b1 modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-\u03b1 pathway and improves lipid metabolism in mice","volume":"8","author":"Takei","year":"2017","journal-title":"J Diabetes Investig"},{"key":"2025120518560398000_14.11.e088862.27","doi-asserted-by":"crossref","DOI":"10.1038\/srep42477","article-title":"Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis","volume":"7","author":"Honda","year":"2017","journal-title":"Sci Rep"},{"key":"2025120518560398000_14.11.e088862.28","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2025120518560398000_14.11.e088862.29","doi-asserted-by":"crossref","unstructured":"Yokote K , Yamashita S , Arai H , et al . Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-alpha Modulator (SPPARMalpha). 2019;20. doi:10.3390\/ijms20030706","DOI":"10.3390\/ijms20030706"},{"key":"2025120518560398000_14.11.e088862.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61933-4"},{"key":"2025120518560398000_14.11.e088862.31","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24376"},{"key":"2025120518560398000_14.11.e088862.32","first-page":"823","article-title":"Good clinical practice guidelines for fine needle aspiration biopsy of the liver: past, present and future","volume":"26","author":"Cadranel","year":"2002","journal-title":"Gastroenterol Clin Biol"},{"key":"2025120518560398000_14.11.e088862.33","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.084"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-088862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T02:56:15Z","timestamp":1764989775000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-088862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,24]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/bmjopen-2024-088862"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088862","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}